United States frontotemporal dementia market is expected to witness robust growth during the forecast period owing to the increasing research & development activities being carried out by drugs manufacturers for the treatment of this disease. Additionally, rising cases of various neurological diseases such as frontotemporal dementia in the country has compelled the government to increase the funding for R&D activities in the healthcare sector. Further, growing geriatric population in the country is also a major factor behind the growth of this market, as people above 65 years of age are more prone to frontotemporal dementia. Moreover, increasing life expectancy rate and availability of advanced care treatment centers such as mental treatment centers and home care administrations are some other key factors, which are fueling the growth of frontotemporal dementia market in United States.

Frontotemporal dementia is a group of disorders that occur when nerve cells in the frontal and temporal lobes of the brain are lost. This causes the lobes to shrink. The disease can affect behaviour, personality, language, and movement of the affected person. Currently, no treatments are available to cure or slow the progression of frontotemporal dementia, but healthcare providers may prescribe medicine to suppress symptoms.

United States frontotemporal dementia market can be segmented based on drug class type, disease type, distribution channel, end user and region. Based on drug class type, the market is categorized into antidepressants and antipsychotics. Currently, the market is witnessing demand for antidepressant drugs as they are highly effective in minimizing the behavioral problems associated with frontotemporal dementia owing to which, the segment is expected to dominate the market until 2025.

Based on distribution channel, United States frontotemporal dementia market is segmented into hospital pharmacy, retail pharmacy, drug store, online pharmacy and others. Among them the retail pharmacy segment is anticipated to undergo high growth during the forecast period as more physicians are recommending drugs such as antidepressants, which are easily available in these stores. 

Major companies operating in United States frontotemporal dementia market include Pfizer Inc., Novartis Corporation, Hoffmann-La Roche, Inc., AstraZeneca Pharmaceuticals LP, Sanofi-Aventis US LLC, Merck & Co., Inc., Alector, Inc., GlaxoSmithKline LLC, Allergan USA, Inc., Eli Lilly and Company, Johnson & Johnson and Mylan Pharmaceuticals, In, among others. The companies are focusing on carrying out extensive clinical trials and R&D activities to launch novel drugs in the market.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of United States frontotemporal dementia market.
  • To forecast United States frontotemporal dementia market based on drug class type, disease type, distribution channel, end user, company and regional distribution.
  • To identify drivers and challenges for United States frontotemporal dementia market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in United States frontotemporal dementia market.
  • To identify and analyze the profile of leading players operating in the United States frontotemporal dementia market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of frontotemporal dementia companies across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated United States frontotemporal dementia market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.


Key Target Audience:

  • Frontotemporal dementia drug manufacturers, companies/partners, hospital/clinics and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to frontotemporal dementia
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as frontotemporal dementia drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, United States frontotemporal dementia market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • United States Frontotemporal Dementia Market, By Drug Class Type:
    • Antidepressants
      • Fluoxetine
      • Fluvoxamine
      • Sertraline
      • Paroxetine
      • Citalopram
      • Bupropion
      • Mitrazepine
    • Antipsychotics
      • Olanzepine
      • Quetiapine
      • Ziprasidone
      • Aripiprazole
      • Risperidone
      • Paliperidone
  • United States Frontotemporal Dementia Market, By Disease Type:
    • Behavior Variant Frontotemporal Dementia (bvFTD)
    • Primary Progressive Aphasia (PPA)
    • Others
  • United States Frontotemporal Dementia Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Drug Store
    • Online Pharmacy
    • Others
  • United States Frontotemporal Dementia Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Others
  • United States Frontotemporal Dementia Market, By Region:
    • North-East
    • Mid-West
    • South
    • West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States frontotemporal dementia market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on United States Frontotemporal Dementia Market

4.    Executive Summary

5.    Voice of Customer

6.    United States Frontotemporal Dementia Market Outlook

6.1.  Market Size & Forecast

6.1.1. By Value

6.2.  Market Share & Forecast

6.2.1.     By Drug Class Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone, Aripiprazole, Risperidone, Paliperidone)

6.2.2.     By Disease Type (Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others)

6.2.3.     By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy, Others)

6.2.4.     By End User (Hospitals, Specialty Clinics, Others)

6.2.5.     By Company (2019)

6.2.6.     By Region

6.3.  Market Attractiveness Index

7.    United States Behavior Variant Frontotemporal Dementia Market Outlook

7.1.  Market Size & Forecast

7.1.1. By Value

7.2.  Market Share & Forecast

7.2.1.     By Drug Class Type

7.2.2.     By Distribution Channel

7.2.3.     By End User

7.3.  Competition Outlook

8.    United States Primary Progressive Aphasia Market Outlook

8.1.  Market Size & Forecast

8.1.1. By Value

8.2.  Market Share & Forecast

8.2.1.     By Drug Class Type

8.2.2.     By Distribution Channel

8.2.3.     By End User

8.3.  Competition Outlook

9.    Market Dynamics

9.1.  Drivers

9.2.  Challenges

10.  Market Trends & Development

11.  Policy & Regulatory Landscape

12.  United States Economic Profile

13.  Competitive Landscape

13.1.              Competition Outlook (Top Companies)

13.1.1.  Pfizer Inc.

13.1.2.  Novartis Corporation

13.1.3.  Hoffmann-La Roche, Inc.

13.1.4.  AstraZeneca Pharmaceuticals LP

13.1.5.  Sanofi-Aventis US LLC

13.1.6.  Merck & Co., Inc.

13.1.7.  Alector, Inc.

13.1.8.  GlaxoSmithKline LLC

13.1.9.  Allergan USA, Inc.

13.1.10.                Eli Lilly and Company

13.1.11.                Johnson & Johnson

13.1.12.                Mylan Pharmaceuticals, Inc.

14.  Strategic Recommendations

15.  About Us & Disclaimer

 (Note: The companies list can be customized based on the client requirements.)

In case you don’t find what you are looking for, please get in touch with our custom research team at [email protected]